公开(公告)号：EP3630818A1

公开(公告)日：2020-04-08

申请号：EP18731372.1

申请日：2018-06-04

申请人： Ablynx NV ,  Merck Patent GmbH

发明人： STEFFENSEN, Soren ,  BESTE, Gerald ,  HERMANS, Guy ,  GÜHRING, Hans ,  LADEL, Christoph ,  TOLEIKIS, Lars

IPC分类号： C07K16/18 ,  C07K16/40 ,  C07K16/46 ,  A61K39/395 ,  A61P19/02

公开(公告)号：EP3380517A1

公开(公告)日：2018-10-03

申请号：EP16805359.3

申请日：2016-11-28

申请人： Ablynx NV

发明人： PATTYN, Els ,  SOMPEL, Ariella Van de ,  MEERTS, Peter ,  BUYSE, Marie-Ange ,  DEWILDE, Maarten ,  BESTE, Gerald ,  VLACH, Jaromir ,  HSU, Jonathan

IPC分类号： C07K16/18 ,  C07K16/28 ,  C07K16/46

CPC分类号： C07K16/2875 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/31

摘要： The present invention relates to immunoglobulins that specifically bind CD40L and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of CD40L and are safe.

公开(公告)号：EP3630178A1

公开(公告)日：2020-04-08

申请号：EP18730690.7

申请日：2018-06-04

申请人： Merck Patent GmbH ,  Ablynx N.V.

发明人： DESCAMPS, Francis ,  BESTE, Gerald ,  HERMANS, Guy ,  GUEHRING, Hans ,  TOLEIKIS, Lars ,  LADEL, Christoph

IPC分类号： A61K39/395 ,  C07K16/40 ,  A61P19/02

公开(公告)号：EP2571901A1

公开(公告)日：2013-03-27

申请号：EP11720539.3

申请日：2011-05-20

申请人： Ablynx N.V. ,  Merck Patent GmbH

发明人： KNUEHL, Christine ,  HOCK, Bjoern ,  HOFMEISTER, Robert ,  BESTE, Gerald ,  REVETS, Hilde Adi Pierrette ,  VERDONCK, Frank Kamiel Delphina ,  CORNELIS, Sigrid Godelieve Victor

IPC分类号： C07K16/32 ,  C07K16/18 ,  C07K16/46 ,  A61K39/395 ,  A61P35/00

CPC分类号： C07K16/2863 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/18 ,  C07K16/32 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94

摘要： The present disclosure relates to amino acid sequences that are directed against (as defined herein) HER3, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively). The disclosure also relates to nucleic acids encoding such amino acid sequences and polypeptides (also referred to herein as “nucleic acids of the invention” or “nucleotide sequences of the invention”); to methods for 10 preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes mentioned herein.

公开(公告)号：EP3630817A1

公开(公告)日：2020-04-08

申请号：EP18730691.5

申请日：2018-06-04

申请人： Merck Patent GmbH ,  Ablynx N.V.

发明人： STEFFENSEN, Soren ,  BESTE, Gerald ,  GUEHRING, Hans ,  TOLEIKIS, Lars ,  LADEL, Christoph ,  LINDEMANN, Sven ,  KELLNER, Roland ,  GUENTHER, Ralf

IPC分类号： C07K16/18 ,  C07K16/40 ,  C07K16/44 ,  A61K39/395 ,  A61P19/02